Open Access Open Access  Restricted Access Subscription Access

An Objectives, Indications, Pharmacodynamics and Pharmacokinetics, Therapeutic Uses, Clinical Efficacy, Mechanism of Action, Administration, Adverse Effects, Drug Interactions, Contra Indications, Toxicity and Health Care Team Outcomes of Benazepril Drug

Srinivas G., Ramanjaneyulu D.V., Satyanarayana Murthy S., Muralinath E., Guruprasad M., Reeta ., Hari Kiran M., Shaik Mahabooob Basha, Kundara Giridhar Reddy, Kasireddy Gautam, Mopoori Kalyan, Sai Charan B., Sainath Reddy T., Ramesh U., Rahul P., Rajitha V.

Abstract


For the treatment of hypertension, benazepril is an angiotensin-converting enzyme (ACE) inhibitor. One important risk factor, particularly for cardiovascular morbidity, is hypertension, which requires efficient management. Healthcare practitioners should be aware of the FDA-approved indications, mechanism of action, and contraindications for benazepril. Additionally, providers need to understand the medication's adverse event profile, dosage, pharmacodynamics, pharmacokinetics, and monitoring needs. Patient safety is improved when pertinent drug interactions are known, especially when patients have renal impairment or belong to particular demographics. When prescribing benazepril, the healthcare team's interprofessional teamwork maximizes therapeutic outcomes. Providing comprehensive knowledge on benazepril aids in the efficient treatment of individuals with hypertension and associated disorders.


Full Text:

PDF

References


Balfour, J. A., & Goa, K. L. (1991). Benazepril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs, 42(3), 511–539. https://pubmed.ncbi.nlm.nih.gov/1655397/

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., ... Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115. https://pubmed.ncbi.nlm.nih.gov/29133356/

Herman, L. L., Padala, S. A., Ahmed, I., & Bashir, K. (2023). Angiotensin-converting enzyme inhibitors (ACEI). In StatPearls. StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/29083700/

Bicket, D. P. (2002). Using ACE inhibitors appropriately. American Family Physician, 66(3), 461–468. https://pubmed.ncbi.nlm.nih.gov/12152964/

Palatini, P., Mos, L., Motolese, M., Mormino, P., Del Torre, M., Varotto, L., Pavan, E., & Pessina, A. C. (1993). Effect of evening versus morning benazepril on 24-hour blood pressure: A comparative study with continuous intraarterial monitoring. International Journal of Clinical Pharmacology, Therapy and Toxicology, 31(6), 295–300. https://pubmed.ncbi.nlm.nih.gov/8325099/

Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 74(2), 1014–1048. https://pubmed.ncbi.nlm.nih.gov/34028994/

Kaiser, G., Ackermann, R., & Sioufi, A. (1989). Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. American Heart Journal, 117(3), 746–751. https://pubmed.ncbi.nlm.nih.gov/2536563/

National Institute of Child Health and Human Development. (2024, November 15). Benazepril. In Drugs and Lactation Database (LactMed®). https://pubmed.ncbi.nlm.nih.gov/30000709/

Reid, J. L., Macdonald, N. J., Lees, K. R., & Elliott, H. L. (1989). Angiotensin-converting enzyme inhibitors in the elderly. American Heart Journal, 117(3), 751–755. https://pubmed.ncbi.nlm.nih.gov/2536564/

Dicpinigaitis, P. V. (2006). Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest, 129(1 Suppl), 169S–173S. https://pubmed.ncbi.nlm.nih.gov/16428695/

Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W. (2006). Efficacy and safety of benazepril for advanced chronic renal insufficiency. New England Journal of Medicine, 354(2), 131–140. https://pubmed.ncbi.nlm.nih.gov/16407508/

Bezalel, S., Mahlab-Guri, K., Asher, I., Werner, B., & Sthoeger, Z. M. (2015). Angiotensin-converting enzyme inhibitor-induced angioedema. American Journal of Medicine, 128(2), 120–125. https://pubmed.ncbi.nlm.nih.gov/25301399/

Jeserich, M., Ihling, C., Allgaier, H. P., Berg, P. A., & Heilmann, C. (2000). Acute liver failure due to enalapril. Herz, 25(7), 689–693. https://pubmed.ncbi.nlm.nih.gov/11185478/

Hashmi, H. R., Jabbour, R., Schreiber, Z., & Khaja, M. (2016). Benazepril-induced agranulocytosis: A case report and review of the literature. American Journal of Case Reports, 17, 425–428. https://pubmed.ncbi.nlm.nih.gov/27324210/

Lindle, K. A., Dinh, K., Moffett, B. S., Kyle, W. B., Montgomery, N. M., Denfield, S. D., & Knudson, J. D. (2014). Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatric Cardiology, 35(3), 499–506. https://pubmed.ncbi.nlm.nih.gov/24052130/


Refbacks

  • There are currently no refbacks.